← All stocks

Decoy Therapeutics Inc.

DCOY Net buying
CIK 0001615219 #5572 in the set updated 21 Sep 2026
Bought (12 mo)
$19.74K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$17.27
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$17.27
2 of 2 sales
Net
+$19.72K
+$19.72K against sales at will

By person

10 insiders · 4 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Rosenblum Mark J
Chief Financial Officer
$16.00K (1)
+$16.00K
11,363
$7.27K
HANISH ARNOLD C
Director
$3.74K (1)
$17.27 (2)
+$3.72K
8,418
$5.38K
+1,792%
PIERCE FREDERICK II
Chief Executive Officer
34,844
$22.29K
+2,409%
Hibner Barbara Louise
Chief Scientific Officer
4,216
$2.70K
Marschel Peter Klaus
Chief Business Officer
3,900
$2.49K
McVicar William K.
Director
3,002
$1.92K
+150,000%
Lieber Jonathan I
Director
2,002
$1.28K
+100,000%
Burleson Tess
Director
2,002
$1.28K
+100,000%
Lammers Paul
Director
2,001
$1.28K
+200,000%
Gauthier Patricia G.
Director
2,000
$1.28K

No percentages here. This company's share count has moved by a factor of 14.4 over the window, from 531,968 to 7,645,594 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
HANISH ARNOLD C
30 Dec 2025
Director
Sell
12
$0.64
$7.68
HANISH ARNOLD C
30 Dec 2025
Director
Sell indirect
15
$0.64
$9.60
Rosenblum Mark J
20 Nov 2025
Exec VP Finance, CFO
Buy
20,000
$0.80
$16.00K
HANISH ARNOLD C
20 Nov 2025
Director
Buy indirect
5,000
$0.75
$3.74K

What was left out

Form 4 filings counted 13
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 2
Transactions with no price 0
Shares from compensation/vesting 65,253
History held since 7 Nov 2016